St. Cloud Hospital seeks patients for heart drug study
The Central Minnesota Heart Center at St. Cloud Hospital is seeking patients to participate in a study comparing the safety and effectiveness of an investigational drug versus Coumadin, a drug that treats atrial fibrillation (AF).
AF is a disorder of the heart rhythm and is associated with an increased risk of stroke, heart attack and death. Medications, such as anticoagulants (Coumadin) and aspirin, are available for patients with AF to reduce this risk. An investigational drug is one not approved by the United States Food and Drug Administration.
"Atrial fibrillation is the most common cardiac arrhythmia and affects more than 1.5 million Americans. By researching alternative treatments, we may be able to give patients more options when it comes to managing their a-fib," said Bernard Erickson, cardiologist at the Central Minnesota Heart Center.
If you are interested or would like more information about the clinical study, contact the Central Minnesota Heart Center at email@example.com or call (320) 251-2700, extension 57560.